| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Merck & Co., Inc. (MRK) has 26 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. MRK is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 456.9K | $54.39M | - | |
| VP | 197.9K | $23.56M | - | |
| Dir | 110.9K | $13.20M | - | |
| Pres | 96.8K | $11.52M | - | |
| CFO | 94.2K | $11.22M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2017 | Holston Michael J | EVP, General Counsel | Sale+OE | 91,959 | $63.96 | $5,881,252.09 | -34.0% | |
| Feb 3, 2017 | Schechter Adam H | EVP &Pres-global Human Health | Sale+OE | 36,335 | $63.73 | $2,315,698.59 | -100% | |
| Feb 3, 2017 | Cech Thomas R | Director | Sale+OE | 5,000 | $63.42 | $317,099.50 | -98.0% | |
| Feb 3, 2017 | Wendell Peter C | Director | Sale+OE | 15,000 | $63.69 | $955,405.50 | -93.8% | |
| Nov 10, 2016 | Frazier Kenneth C | Chairman, President &CEO | Sale+OE | 140,000 | $65.03 | $9,104,486.32 | -12.1% | |
| Nov 7, 2016 | Gerberding Julie L. | EVP Strat Comm, Gl Pub Policy | Sale+OE | 85,523 | $60.02 | $5,133,329.92 | -68.6% | |
| Nov 2, 2016 | Lazarus Rochelle B | Director | Sale+OE | 20,000 | $59.06 | $1,181,200.00 | -81.3% | |
| Nov 2, 2016 | Wendell Peter C | Director | Sale+OE | 5,000 | $59.50 | $297,500.00 | -83.3% | |
| Oct 3, 2016 | Graddick Weir Mirian M | Exe V-p, Hr | Sale+OE | 40,800 | $62.07 | $2,532,582.48 | -31.6% | |
| Sep 1, 2016 | Schechter Adam H | EVP &Pres-global Human Health | Sale+OE | 39,200 | $62.61 | $2,454,308.08 | -100% |